{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,14]],"date-time":"2026-06-14T04:57:47Z","timestamp":1781413067267,"version":"3.54.1"},"reference-count":96,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seminars in Radiation Oncology"],"published-print":{"date-parts":[[2025,1]]},"DOI":"10.1016\/j.semradonc.2024.10.004","type":"journal-article","created":{"date-parts":[[2024,12,12]],"date-time":"2024-12-12T06:03:50Z","timestamp":1733983430000},"page":"87-98","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["Radiation for Multiple Myeloma in the Era of Novel Agents: Indications, Safety, and Dose Selection"],"prefix":"10.1016","volume":"35","author":[{"given":"Samuel C.","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leslie K.","family":"Ballas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.semradonc.2024.10.004_bib0001","doi-asserted-by":"crossref","first-page":"17","DOI":"10.3322\/caac.21763","article-title":"Cancer statistics, 2023","volume":"73","author":"Siegel","year":"2023","journal-title":"CA Cancer J Clin"},{"issue":"1","key":"10.1016\/j.semradonc.2024.10.004_bib0002","doi-asserted-by":"crossref","first-page":"21","DOI":"10.4065\/78.1.21","article-title":"Review of 1027 patients with newly diagnosed multiple myeloma","volume":"78","author":"Kyle","year":"2003","journal-title":"Mayo Clin Proc"},{"issue":"4","key":"10.1016\/j.semradonc.2024.10.004_bib0003","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1016\/j.ijrobp.2018.05.009","article-title":"Radiation therapy for solitary plasmacytoma and multiple myeloma: Guidelines from the International Lymphoma Radiation Oncology Group","volume":"101","author":"Tsang","year":"2018","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"5","key":"10.1016\/j.semradonc.2024.10.004_bib0004","doi-asserted-by":"crossref","first-page":"2516","DOI":"10.1182\/blood-2007-10-116129","article-title":"Improved survival in multiple myeloma and the impact of novel therapies","volume":"111","author":"Kumar","year":"2008","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.semradonc.2024.10.004_bib0005","doi-asserted-by":"crossref","first-page":"1915","DOI":"10.1038\/leu.2016.380","article-title":"Trends in overall survival and costs of multiple myeloma, 2000-2014","volume":"31","author":"Fonseca","year":"2017","journal-title":"Leukemia"},{"issue":"17","key":"10.1016\/j.semradonc.2024.10.004_bib0006","doi-asserted-by":"crossref","first-page":"1928","DOI":"10.1200\/JCO.19.02515","article-title":"Long-term follow-up results of lenalidomide, bortezomib, and dexamethasone induction therapy and risk-adapted maintenance approach in newly diagnosed multiple myeloma","volume":"38","author":"Joseph","year":"2020","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.semradonc.2024.10.004_bib0007","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/0277-5379(89)90001-1","article-title":"Is aggressive chemotherapy more effective in the treatment of plasma cell myeloma?","volume":"25","author":"Bergsagel","year":"1989","journal-title":"Eur J Cancer Clin Oncol"},{"issue":"12","key":"10.1016\/j.semradonc.2024.10.004_bib0008","doi-asserted-by":"crossref","first-page":"3832","DOI":"10.1200\/JCO.1998.16.12.3832","article-title":"Combination chemotherapy versus melphalan plus prednisone as treatment for multiple myeloma: An overview of 6,633 patients from 27 randomized trials. Myeloma Trialists' Collaborative Group","volume":"16","year":"1998","journal-title":"J Clin Oncol"},{"issue":"8","key":"10.1016\/j.semradonc.2024.10.004_bib0009","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1002\/ajh.26590","article-title":"Multiple myeloma: 2022 update on diagnosis, risk stratification, and management","volume":"97","author":"Rajkumar","year":"2022","journal-title":"Am J Hematol"},{"issue":"7","key":"10.1016\/j.semradonc.2024.10.004_bib0010","doi-asserted-by":"crossref","first-page":"867","DOI":"10.4065\/79.7.867","article-title":"Clinical course of patients with relapsed multiple myeloma","volume":"79","author":"Kumar","year":"2004","journal-title":"Mayo Clin Proc"},{"issue":"1","key":"10.1016\/j.semradonc.2024.10.004_bib0011","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1038\/leu.2011.196","article-title":"Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: a multicenter international myeloma working group study","volume":"26","author":"Kumar","year":"2012","journal-title":"Leukemia"},{"issue":"3","key":"10.1016\/j.semradonc.2024.10.004_bib0012","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.clml.2017.12.009","article-title":"Single-center experience in treating patients with t(4;14) multiple myeloma with and without planned frontline autologous stem cell transplantation","volume":"18","author":"Chan","year":"2018","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"12","key":"10.1016\/j.semradonc.2024.10.004_bib0013","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1038\/s41408-019-0254-0","article-title":"Gain of Chromosome 1q is associated with early progression in multiple myeloma patients treated with lenalidomide, bortezomib, and dexamethasone","volume":"9","author":"Schmidt","year":"2019","journal-title":"Blood Cancer J"},{"issue":"3","key":"10.1016\/j.semradonc.2024.10.004_bib0014","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1038\/s41408-019-0191-y","article-title":"Natural history of multiple myeloma with de novo del(17p)","volume":"9","author":"Lakshman","year":"2019","journal-title":"Blood Cancer J"},{"issue":"5","key":"10.1016\/j.semradonc.2024.10.004_bib0015","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1182\/blood-2012-04-403733","article-title":"Proteasome inhibitors in multiple myeloma: 10 years later","volume":"120","author":"Moreau","year":"2012","journal-title":"Blood"},{"issue":"17","key":"10.1016\/j.semradonc.2024.10.004_bib0016","doi-asserted-by":"crossref","first-page":"2359","DOI":"10.1182\/blood-2017-01-725705","article-title":"How I manage the toxicities of myeloma drugs","volume":"129","author":"Delforge","year":"2017","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.semradonc.2024.10.004_bib0017","doi-asserted-by":"crossref","first-page":"3777","DOI":"10.1182\/blood-2005-03-1173","article-title":"Risk factors and kinetics of thrombocytopenia associated with bortezomib for relapsed, refractory multiple myeloma","volume":"106","author":"Lonial","year":"2005","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.semradonc.2024.10.004_bib0018","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1016\/j.urology.2009.07.1215","article-title":"Proteasome inhibitor bortezomib increases radiation sensitivity in androgen independent human prostate cancer cells","volume":"75","author":"Goktas","year":"2010","journal-title":"Urology"},{"issue":"3","key":"10.1016\/j.semradonc.2024.10.004_bib0019","doi-asserted-by":"crossref","first-page":"935","DOI":"10.3892\/ijo.2013.1786","article-title":"Bortezomib-enhanced radiosensitization through the suppression of radiation-induced nuclear factor-kappaB activity in human oral cancer cells","volume":"42","author":"Tamatani","year":"2013","journal-title":"Int J Oncol"},{"issue":"2","key":"10.1016\/j.semradonc.2024.10.004_bib0020","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1016\/j.canlet.2009.05.029","article-title":"MKP1 repression is required for the chemosensitizing effects of NF-kappaB and PI3K inhibitors to cisplatin in non-small cell lung cancer","volume":"286","author":"Cortes-Sempere","year":"2009","journal-title":"Cancer Lett"},{"issue":"7","key":"10.1016\/j.semradonc.2024.10.004_bib0021","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1016\/j.exphem.2005.04.005","article-title":"PS-341-mediated selective targeting of multiple myeloma cells by synergistic increase in ionizing radiation-induced apoptosis","volume":"33","author":"Goel","year":"2005","journal-title":"Exp Hematol"},{"issue":"3","key":"10.1016\/j.semradonc.2024.10.004_bib0022","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1179\/joc.2005.17.3.343","article-title":"Severe acute enteritis in a multiple myeloma patient receiving bortezomib and spinal radiotherapy: Case report","volume":"17","author":"Mohiuddin","year":"2005","journal-title":"J Chemother"},{"issue":"2","key":"10.1016\/j.semradonc.2024.10.004_bib0023","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1016\/j.ijrobp.2009.07.1715","article-title":"Phase I trial of bortezomib and concurrent external beam radiation in patients with advanced solid malignancies","volume":"78","author":"Pugh","year":"2010","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"2","key":"10.1016\/j.semradonc.2024.10.004_bib0024","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1016\/j.ijrobp.2008.08.050","article-title":"Phase I trial using proteasome inhibitor bortezomib and concurrent temozolomide and radiotherapy for central nervous system malignancies","volume":"74","author":"Kubicek","year":"2009","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"5","key":"10.1016\/j.semradonc.2024.10.004_bib0025","doi-asserted-by":"crossref","first-page":"1400","DOI":"10.1016\/j.ijrobp.2005.05.007","article-title":"Inhibition of nuclear factor-kappaB and target genes during combined therapy with proteasome inhibitor bortezomib and reirradiation in patients with recurrent head-and-neck squamous cell carcinoma","volume":"63","author":"Van Waes","year":"2005","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"1","key":"10.1016\/j.semradonc.2024.10.004_bib0026","doi-asserted-by":"crossref","first-page":"7","DOI":"10.3892\/mco.2023.2705","article-title":"Lenalidomide use in multiple myeloma (Review)","volume":"20","author":"Zhang","year":"2024","journal-title":"Mol Clin Oncol"},{"issue":"14","key":"10.1016\/j.semradonc.2024.10.004_bib0027","doi-asserted-by":"crossref","first-page":"2305","DOI":"10.1182\/blood-2013-05-484782","article-title":"Pomalidomide","volume":"122","author":"Lacy","year":"2013","journal-title":"Blood"},{"issue":"19","key":"10.1016\/j.semradonc.2024.10.004_bib0028","first-page":"5565","article-title":"Anti-Vascular endothelial growth factor treatment augments tumor radiation response under normoxic or hypoxic conditions","volume":"60","author":"Lee","year":"2000","journal-title":"Cancer Res"},{"issue":"3","key":"10.1016\/j.semradonc.2024.10.004_bib0029","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1016\/j.ijrobp.2019.10.043","article-title":"Solitary plasmacytoma treated by lenalidomide-dexamethasone in combination with radiation therapy: Clinical outcomes","volume":"106","author":"Mignot","year":"2020","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"1","key":"10.1016\/j.semradonc.2024.10.004_bib0030","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0145-2126(00)00093-X","article-title":"Human CD38: A(r)evolutionary story of enzymes and receptors","volume":"25","author":"Deaglio","year":"2001","journal-title":"Leuk Res"},{"issue":"10245","key":"10.1016\/j.semradonc.2024.10.004_bib0031","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1016\/S0140-6736(20)30734-0","article-title":"Carfilzomib, dexamethasone, and daratumumab versus carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma (CANDOR): results from a randomised, multicentre, open-label, phase 3 study","volume":"396","author":"Dimopoulos","year":"2020","journal-title":"Lancet"},{"issue":"10292","key":"10.1016\/j.semradonc.2024.10.004_bib0032","doi-asserted-by":"crossref","first-page":"2361","DOI":"10.1016\/S0140-6736(21)00592-4","article-title":"Isatuximab, carfilzomib, and dexamethasone in relapsed multiple myeloma (IKEMA): A multicentre, open-label, randomised phase 3 trial","volume":"397","author":"Moreau","year":"2021","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.semradonc.2024.10.004_bib0033","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1182\/blood-2017-06-740944","article-title":"CD38 antibodies in multiple myeloma: back to the future","volume":"131","author":"van de Donk","year":"2018","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.semradonc.2024.10.004_bib0034","doi-asserted-by":"crossref","first-page":"e447","DOI":"10.1016\/S2352-3026(20)30081-8","article-title":"Daratumumab monotherapy in patients with heavily pretreated relapsed or refractory multiple myeloma: Final results from the phase 2 GEN501 and SIRIUS trials","volume":"7","author":"Usmani","year":"2020","journal-title":"Lancet Haematol"},{"issue":"6","key":"10.1016\/j.semradonc.2024.10.004_bib0035","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1016\/j.clml.2014.07.010","article-title":"Feasibility and efficacy of local radiotherapy with concurrent novel agents in patients with multiple myeloma","volume":"14","author":"Shin","year":"2014","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"1","key":"10.1016\/j.semradonc.2024.10.004_bib0036","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.adro.2018.09.009","article-title":"The safety profile of concurrent therapy for multiple myeloma in the modern era","volume":"4","author":"Resende Salgado","year":"2019","journal-title":"Adv Radiat Oncol"},{"issue":"9","key":"10.1016\/j.semradonc.2024.10.004_bib0037","doi-asserted-by":"crossref","DOI":"10.3390\/cancers14092273","article-title":"RR Myelo Point: A retrospective single-center study assessing the role of radiotherapy in the management of multiple myeloma and possible interactions with concurrent systemic treatment","volume":"14","author":"Guerini","year":"2022","journal-title":"Cancers (Basel)"},{"issue":"11","key":"10.1016\/j.semradonc.2024.10.004_bib0038","doi-asserted-by":"crossref","DOI":"10.3390\/cancers15112909","article-title":"Radiotherapy in combination with systemic therapy for multiple myeloma-a critical toxicity evaluation in the modern treatment era","volume":"15","author":"Oertel","year":"2023","journal-title":"Cancers (Basel)"},{"issue":"19","key":"10.1016\/j.semradonc.2024.10.004_bib0039","doi-asserted-by":"crossref","first-page":"1759","DOI":"10.1056\/NEJMoa1112704","article-title":"Continuous lenalidomide treatment for newly diagnosed multiple myeloma","volume":"366","author":"Palumbo","year":"2012","journal-title":"N Engl J Med"},{"issue":"8","key":"10.1016\/j.semradonc.2024.10.004_bib0040","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1182\/blood.2020005288","article-title":"Daratumumab, lenalidomide, bortezomib, and dexamethasone for transplant-eligible newly diagnosed multiple myeloma: the GRIFFIN trial","volume":"136","author":"Voorhees","year":"2020","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.semradonc.2024.10.004_bib0041","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1016\/0360-3016(94)00430-S","article-title":"Hematopoietic stem cell compartment: acute and late effects of radiation therapy and chemotherapy","volume":"31","author":"Mauch","year":"1995","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"3","key":"10.1016\/j.semradonc.2024.10.004_bib0042","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1002\/1097-0142(197309)32:3<699::AID-CNCR2820320324>3.0.CO;2-V","article-title":"Bone marrow regeneration and extension after extended field irradiation in Hodgkin's disease","volume":"32","author":"Rubin","year":"1973","journal-title":"Cancer"},{"issue":"4","key":"10.1016\/j.semradonc.2024.10.004_bib0043","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1080\/09553007014551191","article-title":"Proliferative activity of the stem cells in the bone-marrow of mice after single and multiple irradiations (total-or partial-body exposure)","volume":"18","author":"Croizat","year":"1970","journal-title":"Int J Radiat Biol Relat Stud Phys Chem Med"},{"issue":"1-2","key":"10.1016\/j.semradonc.2024.10.004_bib0044","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0360-3016(77)90003-7","article-title":"Long-term side effects in irradiated patients with Hodgkin's disease","volume":"2","author":"Slanina","year":"1977","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"6","key":"10.1016\/j.semradonc.2024.10.004_bib0045","doi-asserted-by":"crossref","first-page":"1677","DOI":"10.1182\/blood.V73.6.1677.1677","article-title":"Hematopoietic bone marrow recovery after radiation therapy: MRI evaluation","volume":"73","author":"Casamassima","year":"1989","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.semradonc.2024.10.004_bib0046","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.semradonc.2022.11.004","article-title":"Radiation therapy for painful bone metastases: fractionation, recalcification, and symptom control","volume":"33","author":"Tseng","year":"2023","journal-title":"Semin Radiat Oncol"},{"issue":"1","key":"10.1016\/j.semradonc.2024.10.004_bib0047","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.jbo.2014.12.001","article-title":"A definition of \"uncomplicated bone metastases\" based on previous bone metastases radiation trials comparing single-fraction and multi-fraction radiation therapy","volume":"4","author":"Cheon","year":"2015","journal-title":"J Bone Oncol"},{"issue":"4","key":"10.1016\/j.semradonc.2024.10.004_bib0048","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1016\/j.ijrobp.2019.11.033","article-title":"Frequency of complicated symptomatic bone metastasis over a breadth of operational definitions","volume":"106","author":"Alcorn","year":"2020","journal-title":"Int J Radiat Oncol Biol Phys."},{"issue":"3","key":"10.1016\/j.semradonc.2024.10.004_bib0049","doi-asserted-by":"crossref","first-page":"324","DOI":"10.3171\/2010.3.SPINE09459","article-title":"Reliability analysis of the epidural spinal cord compression scale","volume":"13","author":"Bilsky","year":"2010","journal-title":"J Neurosurg Spine"},{"issue":"22","key":"10.1016\/j.semradonc.2024.10.004_bib0050","doi-asserted-by":"crossref","first-page":"E1221","DOI":"10.1097\/BRS.0b013e3181e16ae2","article-title":"A novel classification system for spinal instability in neoplastic disease: an evidence-based approach and expert consensus from the Spine Oncology Study Group","volume":"35","author":"Fisher","year":"2010","journal-title":"Spine (Phila Pa 1976)"},{"issue":"249","key":"10.1016\/j.semradonc.2024.10.004_bib0051","first-page":"256","article-title":"Metastatic disease in long bones. A proposed scoring system for diagnosing impending pathologic fractures","author":"Mirels","year":"1989","journal-title":"Clin Orthop Relat Res"},{"issue":"11","key":"10.1016\/j.semradonc.2024.10.004_bib0052","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1093\/jnci\/dji139","article-title":"Randomized trial of short- versus long-course radiotherapy for palliation of painful bone metastases","volume":"97","author":"Hartsell","year":"2005","journal-title":"J Natl Cancer Inst"},{"issue":"2","key":"10.1016\/j.semradonc.2024.10.004_bib0053","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/S0167-8140(99)00097-3","article-title":"8 Gy single fraction radiotherapy for the treatment of metastatic skeletal pain: randomised comparison with a multifraction schedule over 12 months of patient follow-up. Bone Pain Trial Working Party","volume":"52","year":"1999","journal-title":"Radiother Oncol."},{"issue":"4","key":"10.1016\/j.semradonc.2024.10.004_bib0054","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/S0167-8140(86)80191-8","article-title":"Prospective randomised trial of single and multifraction radiotherapy schedules in the treatment of painful bony metastases","volume":"6","author":"Price","year":"1986","journal-title":"Radiother Oncol"},{"issue":"3","key":"10.1016\/j.semradonc.2024.10.004_bib0055","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1016\/j.radonc.2018.01.003","article-title":"Update of the systematic review of palliative radiation therapy fractionation for bone metastases","volume":"126","author":"Rich","year":"2018","journal-title":"Radiother Oncol"},{"issue":"5","key":"10.1016\/j.semradonc.2024.10.004_bib0056","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1016\/0360-3016(93)90308-I","article-title":"Radiation therapy for the palliation of multiple myeloma","volume":"25","author":"Leigh","year":"1993","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"1","key":"10.1016\/j.semradonc.2024.10.004_bib0057","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.radonc.2011.05.013","article-title":"Reduced dose radiotherapy for local control in non-Hodgkin lymphoma: a randomised phase III trial","volume":"100","author":"Lowry","year":"2011","journal-title":"Radiother Oncol"},{"issue":"3","key":"10.1016\/j.semradonc.2024.10.004_bib0058","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1016\/S1470-2045(20)30686-0","article-title":"4 Gy versus 24 Gy radiotherapy for follicular and marginal zone lymphoma (FoRT): long-term follow-up of a multicentre, randomised, phase 3, non-inferiority trial","volume":"22","author":"Hoskin","year":"2021","journal-title":"Lancet Oncol"},{"issue":"4","key":"10.1016\/j.semradonc.2024.10.004_bib0059","doi-asserted-by":"crossref","first-page":"e400","DOI":"10.1016\/j.prro.2019.02.009","article-title":"Dose selection for multiple myeloma in modern era","volume":"9","author":"Wang","year":"2019","journal-title":"Pract Radiat Oncol"},{"issue":"4","key":"10.1016\/j.semradonc.2024.10.004_bib0060","article-title":"Biological effective radiation dose for multiple myeloma palliation","volume":"8","author":"Meredith","year":"2023","journal-title":"Adv Radiat Oncol"},{"issue":"4","key":"10.1016\/j.semradonc.2024.10.004_bib0061","article-title":"Effective pain control with very low dose palliative radiation therapy for patients with multiple myeloma with uncomplicated osseous lesions","volume":"6","author":"Price","year":"2021","journal-title":"Adv Radiat Oncol"},{"issue":"1","key":"10.1016\/j.semradonc.2024.10.004_bib0062","doi-asserted-by":"crossref","first-page":"59","DOI":"10.3857\/roj.2016.34.1.59","article-title":"Local radiotherapy for palliation in multiple myeloma patients with symptomatic bone lesions","volume":"34","author":"Lee","year":"2016","journal-title":"Radiat Oncol J"},{"issue":"7","key":"10.1016\/j.semradonc.2024.10.004_bib0063","doi-asserted-by":"crossref","first-page":"e355","DOI":"10.3324\/haematol.2019.235804","article-title":"New paradigm for radiation in multiple myeloma: Lower yet effective dose to avoid radiation toxicity","volume":"105","author":"Elhammali","year":"2020","journal-title":"Haematologica"},{"issue":"2","key":"10.1016\/j.semradonc.2024.10.004_bib0064","doi-asserted-by":"crossref","first-page":"S107","DOI":"10.1016\/j.ijrobp.2023.06.068","article-title":"Phase II multi-institutional study of a low-dose (4 Gy) palliative response-adapted radiotherapy regimen for symptomatic bone metastases from multiple myeloma: planned interim analysis of first 40 patients","volume":"117","author":"Ballas","year":"2023","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"9","key":"10.1016\/j.semradonc.2024.10.004_bib0065","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1007\/s00066-017-1154-5","article-title":"Single vs. multiple fraction regimens for palliative radiotherapy treatment of multiple myeloma: A prospective randomised study","volume":"193","author":"Rudzianskiene","year":"2017","journal-title":"Strahlenther Onkol"},{"issue":"1","key":"10.1016\/j.semradonc.2024.10.004_bib0066","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1007\/s00277-005-1078-5","article-title":"Local irradiation prior to stem cell harvest has no influence on CD34+ yield: a quantitative analysis","volume":"85","author":"Rinn","year":"2006","journal-title":"Ann Hematol"},{"issue":"1","key":"10.1016\/j.semradonc.2024.10.004_bib0067","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S1473-0502(03)00097-1","article-title":"Collection of peripheral blood progenitor cells: Analysis of factors predicting the yields","volume":"29","author":"Lee","year":"2003","journal-title":"Transfus Apher Sci"},{"issue":"1","key":"10.1016\/j.semradonc.2024.10.004_bib0068","doi-asserted-by":"crossref","first-page":"37.e1","DOI":"10.1016\/j.jtct.2022.10.020","article-title":"Radiation therapy can be safely incorporated into pretransplantation treatment regimens for patients with multiple myeloma","volume":"29","author":"Damron","year":"2023","journal-title":"Transplant Cell Ther."},{"issue":"10","key":"10.1016\/j.semradonc.2024.10.004_bib0069","doi-asserted-by":"crossref","first-page":"876.e1","DOI":"10.1016\/j.jtct.2021.06.025","article-title":"Local radiation therapy before and during induction delays stem cell mobilization and collection in multiple myeloma patients","volume":"27","author":"Sauer","year":"2021","journal-title":"Transplant Cell Ther."},{"issue":"10","key":"10.1016\/j.semradonc.2024.10.004_bib0070","doi-asserted-by":"crossref","first-page":"1378","DOI":"10.1016\/S1470-2045(21)00428-9","volume":"22","author":"Moreau","year":"2021","journal-title":"Lancet Oncol"},{"issue":"5","key":"10.1016\/j.semradonc.2024.10.004_bib0071","doi-asserted-by":"crossref","first-page":"e238","DOI":"10.1016\/j.clml.2019.02.010","article-title":"Utilization patterns of single fraction radiation therapy for multiple myeloma","volume":"19","author":"Resende Salgado","year":"2019","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"10.1016\/j.semradonc.2024.10.004_bib0072","unstructured":"Network NCC. Multiple myeloma (Version 2.2024). Accessed January 14, 2024, https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/myeloma.pdf"},{"issue":"5","key":"10.1016\/j.semradonc.2024.10.004_bib0073","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1016\/j.ijrobp.2007.08.074","article-title":"Association between bone marrow dosimetric parameters and acute hematologic toxicity in anal cancer patients treated with concurrent chemotherapy and intensity-modulated radiotherapy","volume":"70","author":"Mell","year":"2008","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"2","key":"10.1016\/j.semradonc.2024.10.004_bib0074","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.semradonc.2022.11.005","article-title":"Personalization of radiation therapy in the primary treatment of malignant epidural spinal cord compression (MESCC)","volume":"33","author":"Rades","year":"2023","journal-title":"Semin Radiat Oncol."},{"issue":"21","key":"10.1016\/j.semradonc.2024.10.004_bib0075","doi-asserted-by":"crossref","first-page":"2084","DOI":"10.1001\/jama.2019.17913","article-title":"Effect of single-fraction vs multifraction radiotherapy on ambulatory status among patients with spinal canal compression from metastatic cancer: the SCORAD randomized clinical trial","volume":"322","author":"Hoskin","year":"2019","journal-title":"JAMA"},{"issue":"15","key":"10.1016\/j.semradonc.2024.10.004_bib0076","doi-asserted-by":"crossref","first-page":"3358","DOI":"10.1200\/JCO.2005.08.193","article-title":"Short-course versus split-course radiotherapy in metastatic spinal cord compression: results of a phase III, randomized, multicenter trial","volume":"23","author":"Maranzano","year":"2005","journal-title":"J Clin Oncol"},{"issue":"4","key":"10.1016\/j.semradonc.2024.10.004_bib0077","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1016\/j.ijrobp.2019.08.002","article-title":"Patient-reported outcomes-secondary analysis of the SCORE-2 trial comparing 4 Gy x 5 to 3 Gy x 10 for metastatic epidural spinal cord compression","volume":"105","author":"Rades","year":"2019","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"15","key":"10.1016\/j.semradonc.2024.10.004_bib0078","doi-asserted-by":"crossref","first-page":"3366","DOI":"10.1200\/JCO.2005.04.754","article-title":"Evaluation of five radiation schedules and prognostic factors for metastatic spinal cord compression","volume":"23","author":"Rades","year":"2005","journal-title":"J Clin Oncol"},{"issue":"11","key":"10.1016\/j.semradonc.2024.10.004_bib0079","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1007\/s00066-011-2266-y","article-title":"Dose escalation of radiotherapy for metastatic spinal cord compression (MSCC) in patients with relatively favorable survival prognosis","volume":"187","author":"Rades","year":"2011","journal-title":"Strahlenther Onkol"},{"issue":"3","key":"10.1016\/j.semradonc.2024.10.004_bib0080","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1515\/raon-2016-0029","article-title":"Excellent outcomes after radiotherapy alone for malignant spinal cord compression from myeloma","volume":"50","author":"Rades","year":"2016","journal-title":"Radiol Oncol"},{"issue":"9","key":"10.1016\/j.semradonc.2024.10.004_bib0081","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1038\/s41416-020-0768-z","article-title":"Non-inferiority randomised phase 3 trial comparing two radiation schedules (single vs. five fractions) in malignant spinal cord compression","volume":"122","author":"Thirion","year":"2020","journal-title":"Br J Cancer"},{"issue":"5","key":"10.1016\/j.semradonc.2024.10.004_bib0082","doi-asserted-by":"crossref","first-page":"1452","DOI":"10.1016\/j.ijrobp.2005.10.018","article-title":"Short-course radiotherapy is not optimal for spinal cord compression due to myeloma","volume":"64","author":"Rades","year":"2006","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.semradonc.2024.10.004_bib0083","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1186\/s12885-016-2325-y","article-title":"A predictive tool particularly designed for elderly myeloma patients presenting with spinal cord compression","volume":"16","author":"Rades","year":"2016","journal-title":"BMC Cancer"},{"issue":"11","key":"10.1016\/j.semradonc.2024.10.004_bib0084","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1007\/PL00002317","article-title":"[Role of radiotherapy in the treatment of multiple myeloma]","volume":"176","author":"Mose","year":"2000","journal-title":"Strahlenther Onkol."},{"key":"10.1016\/j.semradonc.2024.10.004_bib0085","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1186\/s13014-015-0374-z","article-title":"Effects of radiotherapy in the treatment of multiple myeloma: a retrospective analysis of a single institution","volume":"10","author":"Matuschek","year":"2015","journal-title":"Radiat Oncol"},{"issue":"9","key":"10.1016\/j.semradonc.2024.10.004_bib0086","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1007\/s00066-008-1808-4","article-title":"Total and single doses influence the effectiveness of radiotherapy in palliative treatment of plasmacytoma","volume":"184","author":"Stolting","year":"2008","journal-title":"Strahlenther Onkol"},{"issue":"1","key":"10.1016\/j.semradonc.2024.10.004_bib0087","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.spinee.2023.09.009","article-title":"Fracture rate after conventional external beam radiation therapy to the spine in multiple myeloma patients","volume":"24","author":"Te Velde","year":"2024","journal-title":"Spine J"},{"issue":"11","key":"10.1016\/j.semradonc.2024.10.004_bib0088","doi-asserted-by":"crossref","first-page":"1832","DOI":"10.1016\/j.spinee.2020.07.004","article-title":"Identifying predictive factors for vertebral collapse fractures in multiple myeloma patients","volume":"20","author":"Zijlstra","year":"2020","journal-title":"Spine J"},{"issue":"7","key":"10.1016\/j.semradonc.2024.10.004_bib0089","doi-asserted-by":"crossref","first-page":"4464","DOI":"10.3390\/curroncol29070355","article-title":"Clinical management of triple-class refractory multiple myeloma: a review of current strategies and emerging therapies","volume":"29","author":"Stalker","year":"2022","journal-title":"Curr Oncol"},{"issue":"8","key":"10.1016\/j.semradonc.2024.10.004_bib0090","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1056\/NEJMoa2024850","article-title":"Idecabtagene vicleucel in relapsed and refractory multiple myeloma","volume":"384","author":"Munshi","year":"2021","journal-title":"N Engl J Med"},{"issue":"10297","key":"10.1016\/j.semradonc.2024.10.004_bib0091","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1016\/S0140-6736(21)00933-8","article-title":"Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b\/2 open-label study","volume":"398","author":"Berdeja","year":"2021","journal-title":"Lancet"},{"issue":"5","key":"10.1016\/j.semradonc.2024.10.004_bib0092","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1089\/hum.2018.001","article-title":"Effective targeting of multiple B-cell maturation antigen-expressing hematological malignances by anti-B-cell maturation antigen chimeric antigen receptor T cells","volume":"29","author":"Friedman","year":"2018","journal-title":"Hum Gene Ther"},{"issue":"23","key":"10.1016\/j.semradonc.2024.10.004_bib0093","doi-asserted-by":"crossref","first-page":"6580","DOI":"10.1158\/1078-0432.CCR-21-0308","article-title":"The safety of bridging radiation with anti-BCMA CAR T-cell therapy for multiple myeloma","volume":"27","author":"Manjunath","year":"2021","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.semradonc.2024.10.004_bib0094","doi-asserted-by":"crossref","DOI":"10.1016\/j.radonc.2023.109933","article-title":"Radiation therapy as a bridging and salvage strategy in patients with relapsed or refractory multiple myeloma undergoing BCMA-targeted CAR T-cell therapy","volume":"189","author":"Ababneh","year":"2023","journal-title":"Radiother Oncol"},{"issue":"4","key":"10.1016\/j.semradonc.2024.10.004_bib0095","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1158\/0008-5472.CAN-17-1788","article-title":"NKG2D-based CAR T cells and radiotherapy exert synergistic efficacy in glioblastoma","volume":"78","author":"Weiss","year":"2018","journal-title":"Cancer Res"},{"issue":"13","key":"10.1016\/j.semradonc.2024.10.004_bib0096","doi-asserted-by":"crossref","first-page":"2871","DOI":"10.1182\/bloodadvances.2020001837","article-title":"Bridging therapy prior to axicabtagene ciloleucel for relapsed\/refractory large B-cell lymphoma","volume":"4","author":"Pinnix","year":"2020","journal-title":"Blood Adv"}],"container-title":["Seminars in Radiation Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1053429624000894?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1053429624000894?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,12,12]],"date-time":"2024-12-12T13:59:49Z","timestamp":1734011989000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1053429624000894"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1]]},"references-count":96,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,1]]}},"alternative-id":["S1053429624000894"],"URL":"https:\/\/doi.org\/10.1016\/j.semradonc.2024.10.004","relation":{},"ISSN":["1053-4296"],"issn-type":[{"value":"1053-4296","type":"print"}],"subject":[],"published":{"date-parts":[[2025,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Radiation for Multiple Myeloma in the Era of Novel Agents: Indications, Safety, and Dose Selection","name":"articletitle","label":"Article Title"},{"value":"Seminars in Radiation Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.semradonc.2024.10.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}